Vyvanse‘s dosing story has a twist most comparison guides skip over: the same three strengths mean something genuinely different depending on why you’re taking the medication. A 30 mg dose might be a standard ADHD starting point for one patient and a titration step toward a much higher binge eating disorder target for another. Understanding both paths — not just “higher dose, stronger effect” — is the key to making sense of where 30, 50, and 70 mg actually fit.
Vyvanse’s Full Dose Ladder
Before comparing these three specific strengths, it helps to see where they sit within Vyvanse’s complete range. Vyvanse capsules are available in 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg strengths, per FDA-approved labeling — 30 mg and 60 mg among them. Dose increases typically proceed in 10 to 20 mg increments at approximately weekly intervals, allowing enough time at each step to assess both effectiveness and tolerability before moving further.
| Dose | Role in ADHD Treatment | Role in BED Treatment |
|---|---|---|
| 30 mg | Standard starting dose for both adults and children ≥6 years | Starting dose, titrated upward from here |
| 50 mg | A common mid-to-upper maintenance dose within the 30-70 mg ADHD range | The low end of the recommended target dose range (50-70 mg/day) |
| 70 mg | Maximum approved daily dose for ADHD | Maximum approved daily dose and the top of the recommended target range |
Why ADHD and BED Dosing Diverge So Much
This is the detail that makes Vyvanse’s dosing genuinely more complex than a typical “higher dose equals more effect” story. Per FDA-approved prescribing information:
- For ADHD, the recommended starting dose is 30 mg once daily, with dosage adjusted in increments of 10 mg or 20 mg at approximately weekly intervals up to a maximum of 70 mg/day — meaning many patients land somewhere in the 30-50 mg range for effective, well-tolerated maintenance treatment, without necessarily needing to reach the ceiling.
- For binge eating disorder, the recommended starting dose is also 30 mg/day, but it’s titrated in larger 20 mg increments specifically toward a target dose of 50 to 70 mg/day — meaning the BED treatment protocol is built around reaching a higher therapeutic dose as standard practice, not just as an option for inadequate responders.
This difference reflects genuinely different clinical research behind each indication — the dose-response relationship studied for binge eating disorder specifically identified the 50-70 mg range as where meaningful symptom reduction was demonstrated in clinical trials, which is different from how ADHD symptom control was studied and dosed.
Vyvanse 30 mg: The Common Starting Point
For most new patients — whether being treated for ADHD or BED — 30 mg is where treatment begins. At this dose:
- Tolerability is the primary focus during the first week or so, since this is often someone’s first exposure to lisdexamfetamine
- Some ADHD patients find this dose provides adequate symptom control on its own and remain here for ongoing maintenance treatment
- For BED, 30 mg is understood from the outset as a starting point rather than a likely final target, given the standard titration path toward 50-70 mg
- Side effects at this dose tend to be milder than at higher strengths, though individual tolerability varies
Vyvanse 50 mg: The Pivot Point
Fifty milligrams plays a somewhat different role depending on the indication:
- For ADHD, this is a common mid-range dose for patients who needed more than 30 mg provided, often reached after one or two titration steps, and many ADHD patients find this an effective long-term maintenance dose without needing to go higher.
- For BED, 50 mg is the lower boundary of the specifically recommended target range (50-70 mg/day), meaning reaching this dose isn’t just “a bit more” — it’s arriving at the dose range where the treatment is specifically designed to work for binge eating symptoms, based on the clinical trials that established BED dosing.
Vyvanse 70 mg: The Ceiling for Both Indications
Seventy milligrams is the maximum approved daily dose for both ADHD and BED — there is no FDA-approved dose above this for either indication. A few things are worth understanding about this ceiling:
- Reaching 70 mg means either that lower doses weren’t providing adequate symptom control, or — specifically for BED — that this dose falls within the standard target range the treatment protocol is built around, not necessarily a sign that something has gone wrong with lower doses.
- Side effects, including appetite suppression, insomnia, and cardiovascular effects, are generally more pronounced at this dose, which is part of why it represents the regulatory ceiling rather than an open-ended “go higher if needed” option.
- For context on Vyvanse’s potency relative to another common stimulant, clinical fact sheets note that lisdexamfetamine 70 mg is roughly equivalent to 30 mg of mixed amphetamine salts (Adderall) — useful context if you’re comparing total stimulant exposure across medications. Our related comparison, Dexedrine vs. Adderall, covers how amphetamine potency comparisons work more broadly.
Dose Adjustments for Kidney Impairment
One detail that doesn’t get enough attention in general dosing discussions: Vyvanse requires specific dose caps for patients with reduced kidney function, since lisdexamfetamine and its active metabolite are cleared through the kidneys. Per FDA labeling, patients with severe renal impairment have a maximum recommended dose of 50 mg/day, and patients with end-stage renal disease (ESRD) have a maximum of 30 mg/day — regardless of what dose might otherwise be indicated for their ADHD or BED symptoms. This is an important detail for your prescriber to factor in if kidney function is a relevant consideration for you.
How Titration Typically Proceeds
Regardless of starting point, a structured titration process is standard for both indications:
- Start at 30 mg once daily in the morning, for both ADHD and BED.
- Allow approximately one week at each dose before adjusting, to assess both effectiveness and side effects.
- For ADHD, increase in 10 or 20 mg increments toward the lowest dose that provides adequate symptom control — not necessarily the maximum.
- For BED, increase in 20 mg increments specifically toward the 50-70 mg target range, since this range reflects where the treatment was studied to be effective for binge eating symptoms.
- Stop increasing once adequate symptom control is achieved, or upon reaching the 70 mg/day maximum — whichever comes first.
What Changes as the Dose Increases
Symptom Coverage
Higher doses generally provide stronger, more sustained symptom control throughout Vyvanse’s roughly 10-to-14-hour duration window, though — as with other stimulants — there’s often a “sweet spot” dose where the benefit-to-side-effect ratio is most favorable, rather than symptom control simply continuing to improve linearly all the way to 70 mg.
Side Effects
Appetite suppression, insomnia, dry mouth, and increased heart rate all tend to become more pronounced at higher doses — a pattern consistent across amphetamine-based medications generally. Our related article, Does Vyvanse Cause Weight Loss?, covers the appetite-related side effects specifically in more depth.
Duration, Not Significantly
Unlike the intensity of effect, Vyvanse’s overall duration — generally cited around 10 to 14 hours — doesn’t change dramatically with dose, since this is governed primarily by how quickly lisdexamfetamine is converted to active dextroamphetamine, a process that happens at a relatively steady rate regardless of the total dose administered.
Switching Between Doses: What to Expect
If your prescriber moves you from one dose to another, expect a period of adjustment rather than an immediate, fully stabilized response. Because Vyvanse’s conversion process happens gradually, some patients notice the full effect of a new dose takes a few days to feel fully established, even though the medication is technically active from the first dose at the new strength. This is a reasonable part of the process, not a sign that something is wrong — your prescriber will typically want a full week or so at a new dose before evaluating whether a further adjustment is needed.
A Realistic Scenario
Consider an adult starting Vyvanse for ADHD at 30 mg. After a week, they notice modest improvement but still struggle with sustained focus during afternoon work blocks. Their prescriber increases the dose to 50 mg. At this dose, focus and task completion improve meaningfully, and side effects — mild appetite suppression, slightly reduced evening hunger — feel manageable. Rather than continuing to 70 mg “just in case it’s even better,” the prescriber and patient agree that 50 mg represents a good balance of symptom control and tolerability, and this becomes the long-term maintenance dose. This illustrates a common pattern: reaching the maximum approved dose isn’t the implicit goal of titration — finding the lowest dose that provides adequate benefit is.
Capsules vs. Chewable Tablets: Does Dosing Differ?
Vyvanse is available both as capsules (10 through 70 mg) and as chewable tablets (10 through 60 mg, notably not available at 70 mg). The two formulations are considered bioequivalent at matching strengths — meaning a 30 mg capsule and a 30 mg chewable tablet deliver a comparable amount of medication — and can generally be substituted on a milligram-for-milligram basis per FDA guidance. If your prescriber or pharmacy needs to switch you between forms at the same strength, this typically doesn’t require a separate titration process, though it’s still worth confirming with your prescriber, particularly if your current dose is at or near the 70 mg ceiling, where the chewable form isn’t an option.
Monitoring Requirements Across the Dose Range
Regardless of which of these three strengths you’re taking, the same core monitoring approach applies, generally with closer attention around dose changes specifically:
- Cardiovascular monitoring, including heart rate and blood pressure at baseline and periodically throughout treatment, given amphetamines’ known cardiovascular effects.
- Growth monitoring in children and adolescents, tracking height and weight against standardized growth charts, since FDA labeling specifically notes that decreased weight is a more frequently reported adverse reaction in younger pediatric patients.
- Psychiatric symptom monitoring, watching for new or worsening anxiety, mood changes, or, rarely, emergent psychotic symptoms, particularly important around dose increases.
- Kidney function consideration, as discussed above, particularly relevant if a higher dose is being considered and any kidney function concerns exist.
- Ongoing reassessment of continued need, standard practice for any Schedule II controlled stimulant regardless of dose.
Insurance and Prior Authorization Considerations
Vyvanse, even as generic lisdexamfetamine, tends to carry a higher price point than some other stimulant options, and insurance plans frequently require prior authorization, particularly at higher doses or for the BED indication specifically, since this is a more recently approved use compared to the longer-established ADHD indication. If your prescriber is planning a titration path toward 50 or 70 mg, it’s worth checking with your insurer in advance about whether a new prior authorization will be needed at each strength change, so coverage isn’t a surprise obstacle right when a dose adjustment is clinically indicated.
How Vyvanse’s Dose Range Compares to Other Amphetamine Medications
| Medication | Typical Dose Range | Approximate Equivalent |
|---|---|---|
| Vyvanse (lisdexamfetamine) | 30-70 mg/day | 70 mg ≈ 30 mg mixed amphetamine salts (Adderall) |
| Adderall (mixed amphetamine salts) | 5-30 mg/day (IR), up to 30 mg/day (XR) | — |
| Dexedrine (dextroamphetamine) | 5-40 mg/day | Roughly comparable to Adderall on a per-milligram dextroamphetamine basis |
These comparisons are approximate reference points rather than precise conversion formulas — switching between any of these medications should always be managed by your prescriber rather than calculated independently, since individual response, formulation differences, and each drug’s specific isomer composition all affect how doses translate in practice. Our related comparison, Dexedrine vs. Adderall, covers this kind of cross-medication comparison in more detail for those two specific drugs.
Frequently Asked Questions
Why would someone need 70 mg instead of 30 mg for the exact same diagnosis?
Individual response to lisdexamfetamine varies significantly based on metabolism, symptom severity, and other factors, so two people with the same diagnosis can genuinely need very different doses to achieve similar symptom control — this isn’t a sign that a lower dose “failed” in any concerning sense.
Is 70 mg Vyvanse considered a high dose?
It’s the maximum FDA-approved dose for both ADHD and BED, so in that specific sense, yes — it represents the regulatory ceiling. Within that approved range, though, many patients safely use 70 mg long-term under appropriate monitoring.
Can I switch directly from 30 mg to 70 mg if 30 mg isn’t working?
No — standard guidance calls for gradual titration in 10-20 mg increments at weekly intervals rather than large jumps, both to monitor tolerability and to find the lowest effective dose rather than overshooting unnecessarily.
Does Vyvanse 50 mg cost significantly more than 30 mg?
Pricing varies by insurance, pharmacy, and whether brand or generic lisdexamfetamine is dispensed, but cost differences between adjacent strengths are typically modest rather than dramatic — insurance formulary placement tends to matter more than the specific milligram strength.
If I’m being treated for BED, will I definitely need to reach 50-70 mg?
The standard titration protocol is built around reaching that target range, since it’s where clinical trials demonstrated meaningful symptom improvement, but individual treatment plans are still determined by your prescriber based on your specific response — not every patient follows the exact same path.
Does the time of day I take Vyvanse change based on my dose?
No — Vyvanse is taken once daily in the morning regardless of dose, since taking it later in the day at any strength raises the risk of sleep disruption given its roughly 10-to-14-hour duration window.
Can a 30 mg dose simply not be “strong enough” to ever work for someone?
It’s possible for 30 mg to be genuinely insufficient for a given person’s ADHD or BED symptoms, which is exactly why the titration process exists — but it’s also common for a dose to need a full week or so to be fairly evaluated before concluding it isn’t adequate, since individual response can take time to fully assess.
The Bottom Line
Vyvanse’s 30, 50, and 70 mg strengths aren’t simply “mild, medium, strong” versions of the same treatment — they represent different points along two genuinely different titration protocols depending on whether you’re being treated for ADHD or binge eating disorder. Understanding which protocol applies to your situation makes it much easier to understand why your prescriber is recommending a particular dose, and why “higher” doesn’t automatically mean “better” outside the specific target range your treatment is built around.
